Wyeth earnings
This article was originally published in The Tan Sheet
Executive Summary
Worldwide Consumer Healthcare net revenue was flat at $598 mil. during the second quarter, Wyeth announces July 20. Net revenue for the division worldwide during the first six months of 2006 decreased 5% to $1.16 bil. when compared to the first six months of 2005. An increase in sales of Advil and Centrum vitamins helped offset losses caused by lower sales of Robitussin, Dimetapp and Advil Cold & Sinus, which resulted from increased retailer restrictions on pseudoephedrine-containing products, the company says. The earnings also reflect the loss of Solgar vitamin sales; the brand was divested to NBTY in the third quarter of 2005 (1"The Tan Sheet" Jan. 16, 2006, p. 13). Wyeth Nutrition's second-quarter net revenue increased 13% over the prior-year period to $300 mil...
You may also be interested in...
Solgar Brand Leads First-Quarter NBTY Sales Growth
NBTY's recently-acquired Solgar vitamin brand continues to drive the firm's sales, the company reported in a first-quarter earnings statement Jan. 9
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.